Trial Profile

A Phase 1b, Multicenter, Open-label Trial of Oncolytic MG1 Expressing MAGE-A3 (MG1-MAGEA3) With Adenovirus Vaccine Expressing MAGE-A3 (Ad-MAGEA3), in Combination With Immune Modulating Therapy in Patients With Metastatic Melanoma or Previously Treated Cutaneous Squamous Cell Carcinoma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide (Primary) ; MG1 MA3 (Primary) ; MG1 MA3 (Primary) ; MG1 MA3 (Primary) ; Pembrolizumab (Primary)
Indications Malignant melanoma; Skin cancer; Squamous cell cancer
Focus Adverse reactions
Acronyms Pelican
Sponsors Turnstone Biologics

01 Apr 2021 Planned initiation date changed from 15 Jan 2020 to 15 Feb 2020.
01 Apr 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
08 Apr 2019 Planned initiation date changed from 15 Jan 2019 to 15 Jan 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com